Captopril: Difference between revisions
(Text replacement - "-->" to "→") |
(→Administration: edited dosage forms, strengths, routes of administration) |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[ACE inhibitor]] | *Type: [[ACE inhibitor]] | ||
*Dosage Forms: | *Dosage Forms: tablet | ||
*Routes of Administration: | *Dosage Strengths: 12.5, 25, 50, 100mg | ||
*Common Trade Names: | *Routes of Administration: PO | ||
*Common Trade Names: Capoten, Captoril | |||
==Adult Dosing== | ==Adult Dosing== | ||
Revision as of 00:16, 12 October 2017
Administration
- Type: ACE inhibitor
- Dosage Forms: tablet
- Dosage Strengths: 12.5, 25, 50, 100mg
- Routes of Administration: PO
- Common Trade Names: Capoten, Captoril
Adult Dosing
- 6.25-150mg PO three times per day
Pediatric Dosing
Safety/efficacy not established in pediatric patients
Special Populations
- Pregnancy Rating: D
- Lactation risk: Infant risk minimal
- Renal dosing: Initial dose should be reduced, titrate in smaller increments
Contraindications
- Allergy to class/drug
- History of ACE-inhibitor induced angioedema
Adverse Reactions
Serious
- Angioedema
- Stevens-Johnson syndrome
- Agranulocytosis, neutropenia
Common
- Hypotension
- Hyperkalemia
- Cough
- Rash
Pharmacology
- Half-life: < 3 hours
- Metabolism:
- Excretion: Renal, dialzable
Mechanism of Action
- Inhibits angiotensin I-converting enzyme, blocks conversion of angiotensin I→ angiotensin II